What is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals is at the forefront of genetic medicine, specializing in the development of therapies that target intractable diseases through gene silencing. The company leverages a diverse portfolio of RNA chemistries and sophisticated delivery methods to induce rapid, deep, and durable knockdown of target genes. By harnessing the natural RNA interference (RNAi) pathway, Arrowhead's therapeutics effectively inhibit the expression of specific genes, thereby controlling the production of disease-associated proteins. This approach positions Arrowhead as a key player in the biopharmaceutical sector, addressing unmet medical needs with cutting-edge genetic technology.
How much funding has Arrowhead Pharmaceuticals raised?
Arrowhead Pharmaceuticals has raised a total of $500M across 1 funding round:
Debt
$500M
Debt (2024): $500M with participation from Sixth Street
Key Investors in Arrowhead Pharmaceuticals
Sixth Street
Sixth Street is a global investment firm with substantial assets under management, known for its investments in prominent companies across various sectors. The firm has a history of significant financial backing, including previous investments in Arrowhead Pharmaceuticals.
What's next for Arrowhead Pharmaceuticals?
The substantial enterprise-level funding and strategic investment signal a pivotal moment for Arrowhead Pharmaceuticals, likely enabling accelerated clinical development, expansion of its therapeutic pipeline, and broader market penetration. This capital infusion is expected to fuel the advancement of its RNAi-based drug candidates through late-stage trials and towards commercialization. The company's focus on silencing genes that cause difficult-to-treat conditions suggests a strategic direction towards tackling significant health challenges, with this latest backing poised to enhance its research and development capabilities and solidify its market position.
See full Arrowhead Pharmaceuticals company page
